The Medical Letter on Drugs and Therapeutics
ADVANCE
RELEASE
ARTICLE
July 17, 2024
View Complete Issue         Table of Contents 2019 
Ganaxolone (Ztalmy) for CDKL5 Deficiency Disorder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ganaxolone (Ztalmy) for CDKL5 Deficiency Disorder
July 17, 2024 (Issue: 5077)
The FDA has approved ganaxolone (Ztalmy – Marinus) for oral treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients ≥2 years old. It is the first drug to be approved in the US for this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ganaxolone (Ztalmy) for CDKL5 Deficiency Disorder
Article code: 5077a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.